{"authors": [["Kulikowski", "Ewelina", "E", "Resverlogix, Calgary, Canada."], ["Calosing", "Cyrus", "C", "Resverlogix, Calgary, Canada."], ["Tsujikawa", "Laura", "L", "Resverlogix, Calgary, Canada."], ["Wasiak", "Sylwia", "S", "Resverlogix, Calgary, Canada."], ["Gilham", "Dean", "D", "Resverlogix, Calgary, Canada."], ["Halliday", "Christopher", "C", "Resverlogix, Calgary, Canada."], ["Johansson", "Jan", "J", "Resverlogix, San Francisco, USA."], ["Sweeney", "Michael", "M", "Resverlogix, San Francisco, USA."], ["Wong", "Norman", "N", "Resverlogix, Calgary, Canada."]], "text": "", "id": "29365466", "date": "2017-08-12", "title": "Apabetalone (RVX-208) may lower CVD events in diabetes mellitus by affecting complement pathway and microbiome activity.", "doi": "10.1016/j.atherosclerosis.2017.06.363", "journal": ["Atherosclerosis", "Atherosclerosis"]}